caninum antigens

were not indicative for protection (10,41,45). selleck inhibitor Assessment of i.n. vaccinated animals confirmed the earlier findings on the protection achieved with recNcPDI (19). Of course, one problem with i.n. vaccination is the restricted amount of antigen which can be administered to mice. Nevertheless, i.n vaccination of mice with the 1 μg recNcPDI antigen conferred protection against cerebral disease (90%), together with low cerebral parasite burden. Association of recNcPDI with the chitosan/alginate or chitosan/alginate-mannose nanogels may have increased this efficacy – with the antigen associated with chitosan/alginate nanogels, 100% of the mice were protected – however, the high number of protected mice with the antigen in the absence of nanogels precluded a clear indication that the nanogels had an added value. It would be necessary to perform additional studies, in which the antigen load per vaccination was titrated, to see whether the limit of inducing protective antibody is lower with nanogel-associated antigen. Nevertheless, the present work demonstrates that nanogel-associated antigen is indeed an efficacious vaccine, and the results from the i.p. vaccination suggest that the nanogels are providing an

added value to the vaccine efficacy. Moreover, quantification of cerebral infection intensities in i.n. vaccinated animals showed that nanogel delivery of the vaccine had an advantage over the nanogel-free vaccine. Although the chitosan/alginate nanogel-associated antigen appeared to be more efficacious than chitosan/alginate-mannose Rucaparib purchase nanogel-associated antigen in limiting cerebral infection compared, the differences were only slight. Others have shown that protective immune responses against experimentally induced neosporosis in acute disease mouse models have been mainly associated with the development of a Th1-type immune response, dominated by IgG2a antibody production and natural killer (NK) cell proliferation with increased IFN-γ production Tideglusib (51,52).

However, there are also reports on protective effects achieved by Th2-type responses in acute disease (40,42–44) and in foetal infection models (44). All these observations support the idea that both Th1 and Th2-driven immune mechanisms can limit disease, at least in the mouse model. Indeed, our own results are showing the presence of a mixed Th1/Th2 response induced in nanogel-delivered vaccine immunized mice, protected from disease, and showing reduced cerebral parasite load. To elaborate on the type of immune response (Th1 or Th2) induced, we analysed the level of cytokine mRNA transcription in splenic tissue. It is important to note that the cytokine pattern described is the combined result of immune responses to both vaccination and infection.